VRS Verisante Technology Inc

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology, today
announced that it has retained Crescendo Communications, LLC ("Crescendo") to
help increase investor awareness throughout North America.


"We are pleased and excited to start working with Verisante, whose breakthrough
skin cancer detection device has the potential to save millions of lives through
early detection. Not only has the Aura(TM) been recently approved for sale in
Canada, Europe and Australia, but U.S. approval is now underway. Moreover, the
technology is applicable to lung, gastro-intestinal, colorectal, cervical and
other cancers, which represent sizable yet untapped markets. For this reason, we
believe it is a great time to begin increasing awareness of Verisante in advance
of a number of important financial and other milestones we expect this year. We
believe the significant potential of their proprietary technology, coupled with
a well-crafted commercialization strategy, will resonate well within the
investment community," commented David Waldman, President & CEO of Crescendo.


"The team at Crescendo has extensive experience within the healthcare market and
a successful track record working with small-cap public companies throughout
North America," said Thomas Braun, President & CEO of Verisante. "We are
confident that Crescendo will help us proactively communicate our business model
and upcoming milestones as we move into the next stage of our development."


The agreement with Crescendo is for a period of 12 months. Under the terms of
the agreement, the Company will pay a consulting fee to Crescendo of $6,000 per
month plus approved expenses incurred on behalf of the Company.


About Crescendo Communications, LLC

Crescendo Communications, LLC, headquartered in New York City with offices in
Beijing, Shanghai and Moscow, is an emerging leader within the investor
relations industry. The firm was founded on a strategic and professional
approach to investor relations that builds awareness of public companies through
tailored outreach programs that target institutional investors, analysts, and
the financial media. The firm's approach is centered around properly educating
investors and cultivating trust in order to uphold and protect their clients'
long-term credibility and reputation on Wall Street and within the global
capital markets.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer
breakthroughs of 2011 by the Canadian Cancer Society.


Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com


YouTube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante


Crescendo Communications, LLC
David Waldman/Natalya Rudman
Investor Relations
(212) 671-1020 x304
VRS@crescendo-ir.com
www.crescendo-ir.com

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Dec 2024 to Jan 2025

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Jan 2024 to Jan 2025